HPV vaccine trial aims to protect women with HIV from cervical cancer
NCT ID NCT06281119
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study tests Cervavac, an HPV vaccine, in women aged 15-25 who are living with HIV. HPV infection can lead to cervical cancer, and women with HIV are at higher risk. The trial compares two-dose and three-dose schedules of Cervavac against a standard vaccine to see how well they work and if they are safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cervavac (quadrivalent HPV vaccine)
What this could lead to
If successful, this could show that Cervavac is safe and effective for women with HIV, helping prevent cervical cancer in a high-risk group.
What could go wrong
This is a Phase 3b study, so results are not yet confirmed. The vaccine may not work as well in women with HIV, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre For Clinical Research, Kemri
Nairobi, 54840-00200, Kenya
-
Clinical HIV Research Unit (CHRU), Helen Joseph Hospital
Johannesburg, 2092, South Africa
-
Manhiça Health Research Center - Manhiça Foundation (CISM-FM)
Manhiça, 1929, Mozambique
-
Partners in Health and Research Development (Phrd)
Thika, 19865-00202, Kenya